[go: up one dir, main page]

BR9714774A - Soluble paclitaxel prodrugs - Google Patents

Soluble paclitaxel prodrugs

Info

Publication number
BR9714774A
BR9714774A BR9714774-5A BR9714774A BR9714774A BR 9714774 A BR9714774 A BR 9714774A BR 9714774 A BR9714774 A BR 9714774A BR 9714774 A BR9714774 A BR 9714774A
Authority
BR
Brazil
Prior art keywords
paclitaxel
onium salts
methods
new
prodrugs
Prior art date
Application number
BR9714774-5A
Other languages
Portuguese (pt)
Inventor
George Digenis
Kenneth H Kortright
Original Assignee
Baker Norton Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baker Norton Pharma filed Critical Baker Norton Pharma
Priority to BR9714774-5A priority Critical patent/BR9714774A/en
Priority claimed from PCT/US1997/010746 external-priority patent/WO1998058927A1/en
Publication of BR9714774A publication Critical patent/BR9714774A/en

Links

Classifications

    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Patente de Invenção: <B>"PRó-DROGAS SOLúVEIS DE PACLITAXEL"<D>. Novos sais de 2'-ónio de paclitaxel atuam como pró-drogas em pacientes mamíferos para produzir paclitaxel in vivo. Os métodos de sintetizar estes sais de ónio são divulgados, como são os métodos de tratar pacientes sofrendo de doenças sensíveis ao paclitaxel, por administração de quantidades efetivas dos sais de ónio, e as composições farmacêuticas contendo os novos sais, as quais são adequadas para a administração a pacientes que necessitem de terapia com paclitaxel.Invention Patent: <B> "PACLITAXEL SOLUBLE PRO-DRUGS" <D>. New 2'-onium salts of paclitaxel act as prodrugs in mammalian patients to produce paclitaxel in vivo. Methods of synthesizing these onium salts are disclosed, as are the methods of treating patients suffering from paclitaxel-sensitive diseases, by administering effective amounts of the onium salts, and the pharmaceutical compositions containing the new salts, which are suitable for administration to patients requiring paclitaxel therapy.

BR9714774-5A 1997-06-20 1997-06-20 Soluble paclitaxel prodrugs BR9714774A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR9714774-5A BR9714774A (en) 1997-06-20 1997-06-20 Soluble paclitaxel prodrugs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BR9714774-5A BR9714774A (en) 1997-06-20 1997-06-20 Soluble paclitaxel prodrugs
PCT/US1997/010746 WO1998058927A1 (en) 1997-06-20 1997-06-20 Soluble prodrugs of paclitaxel

Publications (1)

Publication Number Publication Date
BR9714774A true BR9714774A (en) 2000-07-25

Family

ID=25664977

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9714774-5A BR9714774A (en) 1997-06-20 1997-06-20 Soluble paclitaxel prodrugs

Country Status (1)

Country Link
BR (1) BR9714774A (en)

Similar Documents

Publication Publication Date Title
ATE219363T1 (en) SOLUBLE PRODRUGS OF PACLITAXEL
BR0115109A (en) Therapeutic agents and methods of their use for angiogenesis modulation
ES2178430T3 (en) USE OF GELIFICABLE PHARMACEUTICAL COMPOSITIONS IN PARODONTOLOGY.
BR9815442A (en) Targeted therapeutic release of vitamin D compounds
BR0112591A (en) Acridine derivatives and their application as a medicine
BR9908488A (en) Topiramate pharmaceutical composition
BR0009486A (en) Compounds containing an amide, use of those compounds, pharmaceutical composition, process for the prophylactic or therapeutic treatment of, type II diabetes and process for the preparation of the compounds
ATE235895T1 (en) DRUG DELIVERY SYSTEM CONTAINING A HARD-PACKED, SOLID DRUG BASE
ES2165969T3 (en) AROMATIC CONDENSED NITROGEN COMPOUNDS 5.5 ARIL-SUBSTITUTED AS ANTI-INFLAMMATORY AGENTS.
BR0212008A (en) Use of a compound or a salt, solvate or prodrug thereof, a pharmaceutical composition, a compound or a salt, solvate or prodrug thereof and process for the preparation thereof
DK0975595T3 (en) cocaine analogs
BR0316685A (en) Compositions and methods for the improved mucosal administration of γ2 receptor-fixing peptides and methods for treating and preventing obesity
BR9811818A (en) Use of a compound, compound, and pharmaceutical composition
DE60316779D1 (en) THIADIAZOLYLPIPERAZINE DERIVATIVES SUITABLE FOR THE TREATMENT OF BZW. PREVENTION OF PAIN
BR0000003A (en) Azalides and methods of preparing them
RU95102778A (en) Use of 2-phenyl-3-aroylbenzothiophenes for osseous tissue loss inhibition and serum cholesterol level decrease, pharmaceutical preparation containing 2-phenyl-3-aroylbenzothiophene
BR9914360A (en) N-aralkylaminotetralins as ligands for neuropeptide receptor yy5
BR9810312A (en) Pharmaceutical composition that has marked antitumor activity and / or reduced side effects containing an antitumor agent and a derivative of hydroxy acid
MA27093A1 (en) SULFONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION AS MEDICAMENTS.
BR0315580A (en) Methylene Urea Derivatives
BRPI0410316A (en) compound, pharmaceutical composition, use of the compounds, and method of treating vr1-mediated disorders and for the treatment of pain disorders
BR9808017A (en) Compound, use of the same, pharmaceutical composition, and, processes to treat cancer in a mammal and to manufacture a medicine for the treatment of cancer
HUP0302635A2 (en) Phospholipid derivatives of valproic acid and mixtures thereof
BR9713921A (en) Compound, pharmaceutical composition, process for logician capable of being modulated through factor xa inhibition
CA2302568A1 (en) Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 6A,7A E 8A ANUIDADES.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1836 DE 14/03/2006.